Skip to content

Study · Randomized controlled trial · 2020

3 results

Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.

Gaborit B, Julla JB, Besbes S, Proust M, Vincentelli C, Alos B, Ancel P, Alzaid F, Garcia R, Mailly P, Sabatier F, Righini M and 18 more

Show all authors

Gascon P, Matonti F, Houssays M, Goumidi L, Vignaud L, Guillonneau X, Erginay A, Dupas B, Marie-Louise J, Autié M, Vidal-Trecan T, Riveline JP, Venteclef N, Massin P, Muller L, Dutour A, Gautier JF, Germain S

The Journal of clinical endocrinology and metabolism1 Apr 2020Cited by 69 (Europe PMC)

PMID31589290 (opens in a new tab)DOI10.1210/clinem/dgz069 (opens in a new tab)PepBankPUB-31589290
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes in a 4-week randomized trial, liraglutide had no effect on circulating hematopoietic progenitor cells.

    In plain wordsIn adults with type 2 diabetes, 4 weeks of liraglutide did not change circulating progenitor cell counts.

    Peptide
    Liraglutide
    Outcome
    No significant changeCirculating hematopoietic progenitor cells
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    We further showed no effect of liraglutide on HPCs
    1 context sentence
    Summary · context
    In study 2, a randomized 4-week trial, we assessed the effect of liraglutide on circulating hematopoietic progenitor cells (HPCs), and angio-miRNAs
  2. 02HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes in a 4-week randomized trial, liraglutide had no effect on circulating angio-miRNAs.

    In plain wordsIn adults with type 2 diabetes, 4 weeks of liraglutide did not change blood levels of angiogenesis-related microRNAs.

    Peptide
    Liraglutide
    Outcome
    No significant changeCirculating angio-miRNAs
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    We further showed no effect of liraglutide on HPCs, and angio-miRNAs.
    1 context sentence
    Summary · context
    In study 2, a randomized 4-week trial, we assessed the effect of liraglutide on circulating hematopoietic progenitor cells (HPCs), and angio-miRNAs

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In 3154 patients with type 2 diabetes, exposure to GLP-1 receptor agonists as a class was not associated with severe diabetic retinopathy.

    In plain wordsIn patients with type 2 diabetes, use of GLP-1 receptor agonists as a drug class was not linked to severe diabetic eye disease.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation of GLP-1RA exposure with severe diabetic retinopathy
    Study

    n = 3,154

    Outcome group
    Adverse events · Eye

    Measurements

    Odds ratio
    1.139
    GLP-1RA exposure, severe DR
    95% CI
    0.8 to 1.622
    GLP-1RA exposure, severe DR

    Source sentences

    Summary
    while no association was found with GLP-1RA exposure (o 1.139 [0.800-1.622], P = .47).
    1 context sentence
    Summary · context
    In the cohort of 3154 T2D patients, 10% displayed severe DR.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02686177

Effect of GLP-1 on Angiogenesis

Assistance Publique - Hôpitaux de Parisn = 5018 May 2016 to 28 May 2021

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 15 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.